METASTATIC PROSTATE CANCER
Clinical trials for METASTATIC PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC PROSTATE CANCER trials appear
Sign up with your email to follow new studies for METASTATIC PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Scientists test new prostate cancer imaging drug against existing option
Disease control TerminatedThis early study compared two radioactive drugs used to image and treat prostate cancer that has spread. Seventeen men with advanced prostate cancer received both drugs in a random order. Researchers measured how much radiation reached tumors versus healthy organs like kidneys to…
Matched conditions: METASTATIC PROSTATE CANCER
Phase: EARLY_PHASE1 • Sponsor: Blue Earth Therapeutics Ltd • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Targeted radiation attack tested for Tough-to-Treat prostate cancer
Disease control TerminatedThis study tested whether adding a new targeted radiation drug to standard care could better control advanced prostate cancer that had spread and stopped responding to hormone therapy. The drug, 177Lu-DOTA-rosopatamab, is designed to seek out and deliver radiation directly to pro…
Matched conditions: METASTATIC PROSTATE CANCER
Phase: PHASE3 • Sponsor: Telix Pharmaceuticals (Innovations) Pty Ltd • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Early-Stage trial tests re-engineered immune cells against tough prostate cancers
Disease control TerminatedThis early-stage study tested whether a patient's own immune cells could be modified in a lab to recognize and attack advanced prostate cancer. The treatment, called BPX-601, involved collecting a patient's T-cells, engineering them to target a specific marker on cancer cells, an…
Matched conditions: METASTATIC PROSTATE CANCER
Phase: PHASE1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC